154 related articles for article (PubMed ID: 17382809)
1. WHO must defend patients' interests, not industry.
Cawthorne P; Ford N; Limpananont J; Tienudom N; Purahong W
Lancet; 2007 Mar; 369(9566):974-5. PubMed ID: 17382809
[No Abstract] [Full Text] [Related]
2. [Reference prices].
Rey Abella ME
Aten Primaria; 1999 Sep; 24(5):252-4. PubMed ID: 10590555
[No Abstract] [Full Text] [Related]
3. AIDS drugs. Brazil, Thailand override big pharma patents.
Cohen J
Science; 2007 May; 316(5826):816. PubMed ID: 17495145
[No Abstract] [Full Text] [Related]
4. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
5. Pharmaceuticals and medical devices: cost savings.
Steiner DJ
Issue Brief Health Policy Track Serv; 2013 Dec; ():1-32. PubMed ID: 24482891
[No Abstract] [Full Text] [Related]
6. Pharmaceuticals and medical devices: cost savings.
; Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403843
[No Abstract] [Full Text] [Related]
7. South Africa's moral victory.
Lancet; 2001 Apr; 357(9265):1303. PubMed ID: 11343727
[No Abstract] [Full Text] [Related]
8. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
Health Policy Tracking Service, A Service of Thomson Reuters/West
Issue Brief Health Policy Track Serv; 2011 Jan; ():1-21. PubMed ID: 21374837
[No Abstract] [Full Text] [Related]
9. [Drug manufacturer on the savings package of Ulla Schmidt. "Grip in the moth box of planned economics"].
Schmidt K
MMW Fortschr Med; 2001 Nov; 143(44):52. PubMed ID: 11732398
[No Abstract] [Full Text] [Related]
10. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
Berger JM
Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292
[No Abstract] [Full Text] [Related]
11. The WTO dispute settlement understanding: an unlikely weapon in the fight against AIDS.
Curti AM
Am J Law Med; 2001; 27(4):469-85. PubMed ID: 11837145
[No Abstract] [Full Text] [Related]
12. [Parallel import of drugs for better and for worse].
Krabbe U
Ugeskr Laeger; 2004 Feb; 166(7):611. PubMed ID: 15005051
[No Abstract] [Full Text] [Related]
13. Patent watch.
Harrison C
Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274462
[No Abstract] [Full Text] [Related]
14. Drug shortage crisis resolution.
Duffy E
J Pharm Pract; 2012 Dec; 25(6):619-20. PubMed ID: 23222856
[No Abstract] [Full Text] [Related]
15. World Generic Medicines Congress Americas--a Health Network Communications Conference. 18-21 November 2008, Washington DC, USA.
Bowman M
IDrugs; 2009 Feb; 12(2):92-4. PubMed ID: 19204881
[No Abstract] [Full Text] [Related]
16. [Development costs, regulation and audit in the German SHI Drug Sector].
Kamp F; Walter P; Bücheler R
Gesundheitswesen; 2014 Jan; 76(1):7-18. PubMed ID: 24446140
[No Abstract] [Full Text] [Related]
17. US policy may encourage counterfeit drugs.
Bouchie A
Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826
[No Abstract] [Full Text] [Related]
18. Pharmaceuticals and medical devices: business practices.
Steiner DJ
Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
[No Abstract] [Full Text] [Related]
19. The discovery and development of antiretroviral agents.
Lange JM; Ananworanich J
Antivir Ther; 2014; 19 Suppl 3():5-14. PubMed ID: 25310317
[TBL] [Abstract][Full Text] [Related]
20. The AIDS response catalysing economic and social transformation: the importance of local pharmaceutical production.
Sidibé M
Antivir Ther; 2014; 19 Suppl 3():3-4. PubMed ID: 25310132
[No Abstract] [Full Text] [Related]
[Next] [New Search]
